Showing 4361-4370 of 9406 results for "".
- Sanofi to Present Data on Dupilumab for BP, AD, CSU, PN, Plus Amlitelimabhttps://practicaldermatology.com/news/Sanofi-Present-Data-Dupilumab-BP-AD-CSU-PN-Plus-Amlitelimab/2471384/Sanofi will present 26 abstracts, including one late-breaking and five additional oral presentations, across approved and investigational medicines at the American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, from March 7-11. Presentations in partnership with Regeneron
- Novartis to Present CSU, HS Data for Remibrutinib, Secukinumabhttps://practicaldermatology.com/news/Novartis-Present-CSU-HS-Data-Remibrutinib-Secukinumab/2471383/Novartis announced it will present data from 17 abstracts, including investigator-initiated trials, across its immunology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting and the 2025 American Academy of Allergy Asthma and Immunology (AAAAI) and World Allergy Organizatio
- Pilot Study Suggests Selumetinib's Potential for Cutaneous Neurofibromashttps://practicaldermatology.com/news/pilot-study-suggests-selumetinibs-potential-for-cutaneous-neurofibromas/2471373/A new nonrandomized pilot trial suggested the MEK inhibitor selumetinib was associated with a reduction in the size of cutaneous neurofibromas in patients with Neurofibromatosis Type 1 (NF1). These study, published as a brief rep
- Positive Results Reported From Delgocitinib CHE Trial in Chinahttps://practicaldermatology.com/news/Positive-Results-Reported-Delgocitinib-CHE-Trial-China/2471379/Positive results were announced for the primary endpoint from the double-blind treatment period of the DELTA China phase 3 clinical trial with Anzupgo® (delgocitinib) 20mg/g cream, a topical pan-Janus kinase (JAK) inhibitor, for the potential treatment of Chinese adults and adolescents (aged 12 a
- New INTEGUMENT-PED Results Support Roflumilast Cream for Pediatric ADhttps://practicaldermatology.com/news/phase-3-trial-supports-roflumilast-cream-for-young-children-with-ad/2471293/Arcutis Biotherapeutics announced today that the INTEGUMENT-PED Phase 3 trial had met its primary endpoint, according to a release from the manufacturer. Researchers on the study evaluated the efficacy and safety of roflumilast cr
- Analysis: Sustained Eczema and Psoriasis Remission Achieved with Dupilumabhttps://practicaldermatology.com/news/analysis-sustained-eczema-and-psoriasis-remission-achieved-with-dupilumab/2471286/A new study highlights the potential of dupilumab to deliver sustained remission in children with moderate-to-severe atopic dermatitis (AD). The findings, presented as a poster at the 2025 Masterclasses in Dermatology conference
- Dr. Lain Discusses Predictive Modeling for PsO Biologic Selectionhttps://practicaldermatology.com/news/Dr-Lain-Discusses-Predictive-Modeling-PsO-Biologic-Selection/2471252/Edward (Ted) Lain, MD, MBA, reminded attendees at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, that a method exists for selecting the best class of biologic for each psoriasis patient. “I just want to keep this in the public conscience here,” Dr. Lain said. “There i
- Patient-Centric Guidelines for Generalized Pustular Psoriasis Management Unveiledhttps://practicaldermatology.com/news/patient-centric-guidelines-for-generalized-pustular-psoriasis-management-unveiled/2471251/A global Delphi study has established holistic treatment goals for generalized pustular psoriasis (GPP), integrating both physician and patient perspectives. The consensus study included participants from 24 countries, and acc
- EFFISAYIL 2 Data Suggest Unmet Needs in Generalized Pustular Psoriasis Carehttps://practicaldermatology.com/news/effisayil-2-data-suggest-unmet-needs-in-generalized-pustular-psoriasis-care/2471250/Baseline data from the EFFISAYIL 2 trial suggested that traditional small-molecule therapies fail to adequately address the burden of generalized pustular psoriasis (GPP). The analysis, presented as a poster at Masterclas
- Weight-Loss Drugs Highlighted as 'Easy' Option to Improve PsO Therapieshttps://practicaldermatology.com/news/Weight-Loss-Drugs-Highlighted-Easy-Option-Improve-PsO-Therapies/2471215/Any dermatologist not prescribing weight-loss drugs for psoriasis patients who are obese likely will be soon, according to Mark Lebwohl, MD. Dr. Lebwohl, speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, highlighted data indicating an association between como